XML 31 R22.htm IDEA: XBRL DOCUMENT v3.20.4
Segment Data (Tables)
 3 Months Ended
Dec. 31, 2020
Segment Reporting [Abstract]  
Revenue from External Customers by Geographic Area
Revenues by segment, organizational unit and geographical areas for the three-month periods are detailed below. The Company has no material intersegment revenues.
Three Months Ended December 31,
(Millions of dollars)20202019
United StatesInternationalTotalUnited StatesInternationalTotal
Medical
Medication Delivery Solutions$568 $440 $1,008 $520 $428 $948 
Medication Management Solutions477 152 630 462 113 575 
Diabetes Care150 136 285 139 129 268 
Pharmaceutical Systems79 260 339 84 215 299 
Total segment revenues$1,274 $988 $2,261 $1,204 $886 $2,090 
Life Sciences
Integrated Diagnostic Solutions$1,014 $653 $1,667 $386 $414 $800 
Biosciences120 192 312 152 171 323 
Total segment revenues$1,134 $845 $1,979 $538 $585 $1,123 
Interventional
Surgery$262 $70 $332 $256 $70 $326 
Peripheral Intervention232 193 426 225 170 395 
Urology and Critical Care228 89 317 206 85 291 
Total segment revenues$722 $353 $1,075 $688 $325 $1,012 
Total Company revenues$3,130 $2,186 $5,315 $2,430 $1,795 $4,225 
Financial Information for Company's Segments
Segment income for the three-month periods was as follows:
 Three Months Ended
December 31,
(Millions of dollars)20202019
Income Before Income Taxes
Medical (a)$666 $564 
Life Sciences972 361 
Interventional302 243 
Total Segment Operating Income1,940 1,167 
Acquisitions and other restructurings(50)(86)
Net interest expense(116)(134)
Other unallocated items (b)(616)(553)
Total Income Before Income Taxes$1,157 $394 
(a)The amount for the three months ended December 31, 2019 included a $59 million charge recorded to Cost of products sold, related to the estimate of costs associated with remediation efforts for AlarisTM infusion pumps in the Medication Management Solutions unit.
(b)Primarily comprised of foreign exchange, certain general and administrative expenses and share-based compensation expense.